CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
NCT04681131
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
85
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small-Cell Lung Cancer
Interventions
BIOLOGICAL:
CAB-AXL-ADC
BIOLOGICAL:
PD-1 inhibitor
Sponsor
BioAtla, Inc.